

**DECLARATION FORM ON NOTHING TO DECLARE OR NOTHING NEW TO
DECLARE FOR USE IN THE INFORMATION EXCHANGE**

Measure	Nothing to declare	Nothing new to declare
A, part I	<input type="checkbox"/>	<input type="checkbox"/>
A, part 2 (i)	<input type="checkbox"/>	<input type="checkbox"/>
A, part 2 (ii)	<input type="checkbox"/>	<input type="checkbox"/>
A, part 2 (iii)	<input type="checkbox"/>	<input type="checkbox"/>
B (i)	<input type="checkbox"/>	<input type="checkbox"/>
B (ii)	<input type="checkbox"/>	<input type="checkbox"/>
C	<input type="checkbox"/>	<input type="checkbox"/>
D	<input type="checkbox"/>	<input type="checkbox"/>
E	<input type="checkbox"/>	<input type="checkbox"/>
F	<input type="checkbox"/>	<input type="checkbox"/>
G	<input type="checkbox"/>	<input type="checkbox"/>

(Please mark the appropriate box(es) for each measure, with a tick.)

Date: _____

State Party to the Convention: _____

CONFIDENCE BUILDING MEASURE A (Part I)

Form A, part 1

Exchange of data on research centres and laboratories¹

1. Name(s) of facility² _____
2. Responsible public or private organization or company _____

3. Location and postal address _____

4. Source(s) of financing of the reported activity, including indication if the activity is wholly or partly financed by the Ministry of Defence

5. Number of maximum containment units³ within the research centre and/or laboratory, with an indication of their respective size (m²)

6. If no maximum containment unit, indicate highest level of protection

7. Scope and general description of activities, including type(s) of micro-organisms and/or toxins as appropriate

¹The containment units which are fixed patient treatment modules, integrated with laboratories, should be identified separately.

²For facilities with maximum containment units participating in the national biological defence research and development programme, please fill in name of facility and mark "Declared in accordance with Form A, part 2 (iii)".

³In accordance with the 1983 WHO Laboratory Biosafety Manual, or equivalent

National biological defence research and development programme Declaration

Is there a national programme to conduct biological defence research and development within the territory of the State Party, under its jurisdiction or control anywhere? Activities of such a programme would include prophylaxis, studies on pathogenicity and virulence, diagnostic techniques, aerobiology, detection, treatment, toxinology, physical protection, decontamination and other related research.

Yes/No

If the answer is Yes, complete Form A, part 2 (ii) which will provide a description of the programme.

National biological defence research and development programme

Description

1. State the objectives and funding of the programme and summarize the principal research and development activities conducted in the programme. Areas to be addressed shall include: prophylaxis, studies on pathogenicity and virulence, diagnostic techniques, aerobiology, detection, treatment, toxinology, physical protection, decontamination and other related research.

2. State the total funding for the programme and its source.

3. Are aspects of this programme conducted under contract with industry, academic institutions, or in other non-defence facilities?

Yes/No

4. If yes, what proportion of the total funds for the programme is expended in these contracted or other facilities?

5. Summarize the objectives and research areas of the programme performed by contractors and in other facilities with the funds identified under paragraph 4.

6. Provide a diagram of the organizational structure of the programme and the reporting relationships (include individual facilities participating in the programme).

7. Provide a declaration in accordance with Form A, part 2 (iii) for each facility, both governmental and non-governmental, which has a substantial proportion of its resources devoted to the national biological defence research and development programme, within the territory of the reporting State, or under its jurisdiction or control anywhere.

National biological defence research and development programme

Facilities

Complete a form for each facility declared in accordance with paragraph 7 in Form A, part 2 (ii).

In shared facilities, provide the following information for the biological defence research and development portion only.

1. What is the name of the facility?

2. Where is it located (include both address and geographical location)?

3. Floor area of laboratory areas by containment level:
BL2 _____ (sqM)
BL3 _____ (sqM)
BL4 _____ (sqM)
Total laboratory floor area _____ (sqM)

4. The organizational structure of each facility.
 - (I) Total number of personnel _____

 - (ii) Division of personnel:
Military _____
Civilian _____

 - (iii) Division of personnel by category:
Scientists _____
Engineers _____
Technicians _____
Administration and support staff _____

- (iv) List the scientific disciplines represented in the scientific/engineering staff.
- (v) Are contractor staff working in the facility? If so, provide an approximate number.
- (vi) What is (are) the source(s) of funding for the work conducted in the facility, including indication if activity is wholly or partly financed by the Ministry of Defence?
- (vii) What are the funding levels for the following programme areas:

Research

Development

Test and evaluation

- (viii) Briefly describe the publication policy of the facility:
- (ix) Provide a list of publicly-available papers and reports resulting from the work during the previous 12 months. (To include authors, titles and full references.)

5. Briefly describe the biological defence work carried out at the facility, including type(s) of micro-organisms* and/or toxins studied, as well as outdoor studies of biological aerosols.

*Including viruses and prions.

**Background information on outbreaks of reportable
infectious diseases**

Disease	Number of cases per year				
	1988	1989	1990	1991	1992

Information on outbreaks of infectious diseases and similar occurrences, that seem to deviate from the normal pattern

1. Time of cognizance of the outbreak
2. Location and approximate area affected
3. Type of disease/intoxication
4. Suspected source of disease/
intoxication
5. Possible causative agent(s)
6. Main characteristics of systems
7. Detailed symptoms, when applicable
 - respiratory
 - circulatory
 - neurological/behavioural
 - intestinal
 - dermatological
 - nephrological
 - other
8. Deviation(s) from the normal pattern as regards
 - type
 - development
 - place of occurrence
 - time of occurrence
 - symptoms
 - virulence pattern

- drug resistance pattern
 - agent(s) difficult to diagnose
 - presence of unusual vectors
 - other
9. Approximate number of primary cases
10. Approximate number of total cases
11. Number of deaths
12. Development of the outbreak
13. Measures taken

4. **CONFIDENCE-BUILDING MEASURE "C":**

- **Encouragement of publication of results and promotion of use of knowledge**

At the Third Review Conference it was agreed that States parties continue to implement the following:

"Encouragement of publication of results of biological research directly related to the Convention, in scientific journals generally available to States parties, as well as promotion of use for permitted purposes of knowledge gained in this research."

Modalities

The Third Review Conference agreed on the following:

1. It is recommended that basic research in biosciences, and particularly that directly related to the Convention should generally be unclassified and that applied research to the extent possible, without infringing on national and commercial interests, should also be unclassified.
2. States parties are encouraged to provide information on their policy as regards publication of results of biological research, indicating, inter alia, their policies as regards publication of results of research carried out in research centres and laboratories subject to exchange of information under item A and publication of research on outbreaks of diseases covered by item B, and to provide information on relevant scientific journals and other relevant scientific publications generally available to States parties.
3. The Third Review Conference discussed the question of cooperation and assistance as regards the safe handling of biological material covered by the Convention. It concluded that other international forums were engaged in this field and expressed its support for efforts aimed at enhancing such cooperation.

Active promotion of contacts

1. Planned international conferences, symposia, seminars, and other similar forums for exchange

For each such event, the following information should be provided:

- name of the conference, etc.
- arranging organization(s), etc.
- time
- place
- main subject(s) for the conference, etc.
.....
- conditions for participation
- point of contact for further information, registration, etc.
.....
.....

2. Information regarding other opportunities

.....
.....
.....

Declaration of legislation, regulations and other measures

<u>Relating to</u>	<u>Legislation</u>	<u>Regulations</u>	<u>Other measures</u>	<u>Amended since last year</u>
(a) Development, production stockpiling, acquisition or retention of microbial or other biological agents, or toxins, weapons, equipment and means of delivery specified in Article I	YES/NO	YES/NO	YES/NO	YES/NO
(b) Exports of micro-organisms* and toxins	YES/NO	YES/NO	YES/NO	YES/NO
(c) Imports of micro-organisms* and toxins	YES/NO	YES/NO	YES/NO	YES/NO

* Micro-organisms pathogenic to man, animals and plants in accordance with the Convention.

Declaration of past activities in offensive and/or defensive biological research and development programmes

1. Date of entry into force of the Convention for the State party.
2. Past offensive biological research and development programmes:
 - YES - NO
 - Period(s) of activities
 - Summary of the research and development activities indicating whether work was performed concerning production, test and evaluation, weaponization, stockpiling of biological agents, the destruction programme of such agents and weapons, and other related research.
3. Past defensive biological research and development programmes:
 - YES - NO
 - Period(s) of activities
 - Summary of the research and development activities indicating whether or not work was conducted in the following areas: prophylaxis, studies on pathogenicity and virulence, diagnostic techniques, aerobiology, detection, treatment, toxinology, physical protection, decontamination, and other related research, with location if possible.

Declaration of vaccine production facilities

1. Name of facility:
2. Location (mailing address):
3. General description of the types of diseases covered: